Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests
Authors' conclusion
Our findings suggest that apelin decreases to a greater extent in PP compared with AVP-D upon copeptin stimulation tests. However, copeptin remains the best marker to differentiate AVP-D from PP.
Study context
- Population
- Outpatients with arginine vasopressin deficiency (AVP-D) and primary polydipsia (PP), University Hospital Basel, undergoing copeptin stimulation tests with hypertonic saline and arginine infusionanalysed
- Participants
- 38 outpatients
- Comparison
- PP vs AVP-D: apelin changes upon copeptin stimulation tests
- PPn = 23
- AVP-Dn = 15reference
- Primary endpoint
- Absolute difference in apelin between baseline and peak of copeptin stimulation tests
Methodological detailsmulticentre
- Multicentre
Primary result
As reported in the abstract
Change in apelin upon hypertonic saline · baseline to peak
PP
−241
median · IQR −326–-124 · pmol/L
AVP-D
−47.2
median · IQR −198–5.86 · pmol/L
P = 0.022
Secondary outcomes
Baseline apelin
Median, pmol/L
| Outcome | PP | AVP-D | P value |
|---|---|---|---|
| Change in apelin upon arginine · baseline to peak | −39.2 (IQR −96.4–39.8) | 25.8 (IQR 2.8–113.0) | P = 0.1 |
Baseline apelin
- No difference between PP and AVP-D
AUC to differentiate PP from AVP-D, hypertonic saline test: copeptin vs apelin
- AUC copeptin
- 97.1% (95% CI, 90.5-100)
- AUC apelin
- 49.3% (95% CI, 30.4-68.1)
- Copeptin vs apelin
- P < 0.001
AUC to differentiate PP from AVP-D, arginine test: copeptin vs apelin
- AUC copeptin
- 97.1% (95% CI: 79.6-98.0)
- AUC apelin
- 60.5% (95% CI: 39.8-80.0)
- Copeptin vs apelin
- P = 0.007
Original publication
Apelin levels in patients with polyuria-polydipsia syndrome upon copeptin stimulation tests. Eur J Endocrinol. Published 19 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →